Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

 Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Shots:

  • Purdue to receive one-time payment from Eisai, while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and commercialization rights for lemborexant, previously held by Purdue in the deal of Aug’15
  • The termination enables Purdue to focus on oncology, non-opioid pain & CNS programs. In Aug’15, Eisai granted WW development & commercialization rights of lemborexant to Purdue and shared clinical study & development costs
  • Lemborexant is a dual orexin receptor antagonist used for insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer’s disease. The US FDA accepted its NDA application with PDUFA date on Dec 27, 2019

Click here to read full press release/ article | Ref: Purdue Pharma | Image: Twitter